Clinical data | |
---|---|
Trade names | nefopam medisol |
AHFS/Drugs.com | International Drug Names |
Routes of administration | intramuscular, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Low[1] |
Protein binding | 70–75% (mean 73%)[1][2] |
Metabolism | Liver (N-demethylation, others)[1] |
Metabolites | Desmethylnefopam, others[1] |
Elimination half-life | Nefopam: 3–8 hours[1] Desmethylnefopam: 10–15 hours[1] |
Excretion | Urine: 79.3%[1] Feces: 13.4%[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.033.757 |
Chemical and physical data | |
Formula | C17H19NO |
Molar mass | 253.345 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Nefopam, sold under the brand name Acupan among others, is a centrally acting, non-opioid painkilling medication, with central stimulant and sympathomimetic properties that is primarily used to treat moderate to severe pain.[3]
Nefopam acts in the brain and spinal cord to relieve pain via novel mechanisms: antinociceptive effects from triple monoamine reuptake inhibition, and antihyperalgesic activity through modulation of glutamatergic transmission.[4]
RevPharm2016
was invoked but never defined (see the help page).